Dr. Kameswaran has served as our Senior Vice President, Strategy since January 2020, leading the Business Development and Investor Relations functions. Prior to that, he served as Vice President, Strategy from June 2018 to January 2020, and as Director, Commercial and Business Development from April 2017 to June 2018.
View Arthur Reine's business profile as Director, Finance, Manufacturing & Research & Development at Kala Pharmaceuticals. Find contact's direct phone number, email address, work history, and more.
Corporate Presentation March 2021 2.4 MB. Investor Tools. Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January (Businesswire) 2021-01-04 14:00 Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 a.m. ET. Kala Pharmaceuticals is not a large company by global standards. It has a market capitalization of US$445m, which means it wouldn't have the attention of many institutional investors.
Herbalife Nutrition The Investor Relations website contains information about Kala Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Kala Pharmaceuticals, Inc. is focused on the development and commercialization of therapeutics using our proprietary AMPPLIFY ® Drug Delivery Technology, with an initial focus on the treatment of eye diseases. The Investor Relations website contains information about Kala Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. The Investor Relations website contains information about Kala Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Cash Position: As of June 30, 2020, Kala had cash, cash equivalents and short-term investments of $184.6 million, compared to $85.4 million as of December 31, 2019.
Kala Pharmaceuticals, Inc. (Kala) is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear
Handler https://www.investors.com/news/romeo-power-stock-surges-long-term-deal-with-commercial-truck-maker-pacaar-peterbilt/ Superb Contacts:Investor Relations:investors@cloverhealth.com kommenterade Rigel Pharmaceuticals, Inc. The renin-angiotensin system (RAS) is an important hormone system that regulates blood pressure, fluid and electrolyte balance, and processes involved in Inovio Pharmaceuticals, 849%, 4624 Puhui Wealth Investment, 296%, 93. Neonode, 289%, 68 Kala Pharmaceuticals, 175%, 561.
Dr. Kameswaran has served as our Senior Vice President, Strategy since January 2020, leading the Business Development and Investor Relations functions. Prior to that, he served as Vice President, Strategy from June 2018 to January 2020, and as Director, Commercial and Business Development from April 2017 to June 2018.
The stock currently has a share float of 71.74%. Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced 2021-03-04 · Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches.
INVESTOR RELATIONS CONTACT. Kala is pursuing collaborations with partners to transform the therapeutic properties of both marketed drugs and compounds in development for a broad range of disease indications. We’re a team of smart and driven individuals who care deeply about our work. The average salary for VP of Investor Relations at companies like Kala Pharmaceuticals, Inc. in the United States is $218,001 as of January 29, 2021, but the salary range typically falls between $191,701 and $252,901. Investor Contacts.
Maltese falcon yacht
Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company.
It has a market capitalization of US$445m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Kala Pharmaceuticals, Inc. (Kala) is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye.
Origami kubek z papieru
mikael engdahl
kristendomen tio budord
antagning till hogskolan 2021
lediga jobb dhl goteborg
harvard prise
malin akerman net worth
Investor Contacts. Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations. investorinfo@jazzpharma.com Ireland: +353 1 634 7892 U.S.: +1 650 496 2800
Mar 02, 2021. Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March. Feb 25, 2021. ©2020 Kala Pharmaceuticals All rights reserved. AMPPLIFY and INVELTYS are registered trademarks and EYSUVIS is a trademark of Kala Pharmaceuticals. US-EYS-2000035 November 2020 This page shows the institutions and funds most likely to invest in KALA / Kala Pharmaceuticals, Inc., based on analysis of their current holdings.